Certara Inc (CERT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Certara Inc (CERT) has a cash flow conversion efficiency ratio of 0.027x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($28.82 Million) by net assets ($1.06 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Certara Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Certara Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CERT total debt and obligations for a breakdown of total debt and financial obligations.
Certara Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Certara Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xiamen International Airport Co Ltd
SHG:600897
|
0.043x |
|
Hubei Heyuan Gas Co Ltd
SHE:002971
|
0.087x |
|
Northern Dynasty Minerals Ltd
TO:NDM
|
-0.089x |
|
Aktis Oncology, Inc. Common stock
NASDAQ:AKTS
|
0.097x |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
0.042x |
|
Shanghai Aladdin Biochemical Technology Co. Ltd. A
SHG:688179
|
N/A |
|
Suzhou Xianglou New Material Co. Ltd.
SHE:301160
|
-0.019x |
|
Asiana Airline
KO:020560
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Certara Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Certara Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Certara Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.06 Billion | $96.33 Million | 0.091x | +19.24% |
| 2024-12-31 | $1.06 Billion | $80.47 Million | 0.076x | -3.85% |
| 2023-12-31 | $1.05 Billion | $82.75 Million | 0.079x | -7.77% |
| 2022-12-31 | $1.08 Billion | $92.54 Million | 0.086x | +47.88% |
| 2021-12-31 | $1.04 Billion | $60.39 Million | 0.058x | +6.34% |
| 2020-12-31 | $822.13 Million | $44.81 Million | 0.055x | -29.47% |
| 2019-12-31 | $492.05 Million | $38.02 Million | 0.077x | +228.51% |
| 2018-12-31 | $492.77 Million | $11.59 Million | 0.024x | -- |
About Certara Inc
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pha… Read more